BVS241220C17500
- 0.60
- 0.000.00%
Bioventus Newsroom
Earnings Call: Bioventus Reports Robust Q3 Growth, Raises Full-year Guidance
Bioventus Is Maintained at Buy by Canaccord Genuity
Bioventus Analyst Ratings
Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating, Announces Target Price $17
CCORF Maintains Bioventus(BVS.US) With Buy Rating, Raises Target Price to $15
J.P. Morgan Maintains Bioventus(BVS.US) With Sell Rating, Announces Target Price $12
Bioventus (BVS) Gets a Sell From J.P. Morgan
Q3 2024 Bioventus Inc Earnings Call
Express News | Bioventus Inc : Canaccord Genuity Raises Target Price to $15 From $12
Bioventus Reports Strong Revenue Growth in Q3 2024
Dow Jumps 400 Points; Yum! Brands Posts Downbeat Earnings
Bioventus Inc. (BVS) Q3 2024 Earnings Call Transcript Summary
Bioventus Inc. (BVS) Q3 2024 Earnings Call Transcript
12 Health Care Stocks Moving In Tuesday's Intraday Session
Bioventus Down Nearly 19%, on Pace for Largest Percent Decrease Since August 2023 -- Data Talk
Nasdaq Gains Over 100 Points; US Trade Deficit Widens In September
Bioventus Shares Are Trading Lower. The Company Reported Q3 Financial Results.
Bioventus Non-GAAP EPS of $0.06, Revenue of $139M Beats by $5.76M
Bioventus: Q3 Earnings Snapshot
Bioventus | 10-Q: Q3 2024 Earnings Report